Monte Rosa Therapeutics Q3 EPS $(0.43) Up From $(4.29) YoY
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share. This is a 89.98 percent increase over losses of $(4.29) per share from the same period last year.
66 Biggest Movers From Friday
Gainers
Bakkt Holdings, Inc. (NASDAQ: BKKT) shares surged 66.1% to close at $42.52 on Friday on continued volatility after the company recently announced partnerships with Mastercard and Fiserv.
SVB Leerink Initiates Coverage On Monte Rosa Therapeutics with Market Perform Rating, Announces Price Target of $20
SVB Leerink analyst Andrew Berens initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Market Perform rating and announces Price Target of $20.
Biotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment
Photo by Dimitri Karastelev on Unsplash
54 Biggest Movers From Yesterday
Gainers
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) shares jumped 111.8% to settle at $27.17 on Wednesday after jumping 50% on Tuesday.
The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 7)
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
The Daily Biotech Pulse: Early Approval For Ascendis’ Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 25)